Farzad Haerizadeh oversees and manages large molecule and cell therapy pipelines and programs at BioArdis.
Farzad has more than 20 years of experience in the life sciences and biotech industries with a strong focus on adaptive cellular and immuno-oncology products including CAR-T, allogeneic CAR-T, allogeneic ‘off the shelf’ stem cell/iPSC products, mammalian genome editing and synthetic biology. In the past several years he served as the VP of preclinical IO platform development in F1Oncology/ Exuma Inc.
He also held multiple key R&D roles in several pharma/biotech companies such as Intrexon, Synthetic Genomics, Life Technologies Corporation (Thermifisher Scientific) and Codexis Inc. where he initiated and directed multiple cutting-edge adaptive cell therapy (engineering T cells, T cell receptors (TCRs), NK cells) and therapeutics discovery platforms, xenotransplantation, protein engineering and industrial enzymes evolution programs. He is also experienced in bio-manufacturing and product development.
Farzad holds a PhD and a postdoctoral fellowship in Molecular, Cellular & Systems Biology from the University of Melbourne, Australia, and a postdoctoral fellowship from Stanford University, California.